Rajeev Saggar Sells 2,526 Shares of Liquidia Technologies, Inc. (NASDAQ:LQDA) Stock

Liquidia Technologies, Inc. (NASDAQ:LQDA - Get Free Report) insider Rajeev Saggar sold 2,526 shares of the firm's stock in a transaction that occurred on Monday, July 21st. The stock was sold at an average price of $14.54, for a total transaction of $36,728.04. Following the sale, the insider owned 268,887 shares in the company, valued at approximately $3,909,616.98. This trade represents a 0.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Rajeev Saggar also recently made the following trade(s):

• On Monday, July 14th, Rajeev Saggar sold 5,327 shares of Liquidia Technologies stock. The shares were sold at an average price of $14.28, for a total transaction of $76,069.56.

Liquidia Technologies Price Performance

Shares of NASDAQ LQDA traded up $0.70 during midday trading on Friday, reaching $19.47. The company's stock had a trading volume of 2,482,698 shares, compared to its average volume of 1,583,000. The company has a current ratio of 2.93, a quick ratio of 2.91 and a debt-to-equity ratio of 2.08. The company has a 50 day moving average price of $14.83 and a 200 day moving average price of $14.63. Liquidia Technologies, Inc. has a one year low of $8.26 and a one year high of $19.76. The company has a market cap of $1.66 billion, a price-to-earnings ratio of -12.32 and a beta of -0.01.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.03). The firm had revenue of $3.12 million during the quarter, compared to analysts' expectations of $3.23 million. Liquidia Technologies had a negative return on equity of 177.91% and a negative net margin of 903.80%. On average, equities research analysts expect that Liquidia Technologies, Inc. will post -1.51 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. HC Wainwright lifted their price target on shares of Liquidia Technologies from $29.00 to $35.00 and gave the stock a "buy" rating in a research note on Wednesday, May 28th. Wells Fargo & Company raised their price objective on shares of Liquidia Technologies from $23.00 to $25.00 and gave the stock an "overweight" rating in a report on Thursday, June 12th. Wall Street Zen raised shares of Liquidia Technologies from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Bank of America decreased their price objective on shares of Liquidia Technologies from $25.00 to $23.00 and set a "buy" rating for the company in a report on Wednesday, June 11th. Finally, BTIG Research reissued a "buy" rating on shares of Liquidia Technologies in a report on Tuesday, May 27th. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $26.89.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LQDA. Hurley Capital LLC bought a new stake in Liquidia Technologies in the first quarter worth approximately $32,000. GAMMA Investing LLC grew its position in Liquidia Technologies by 65.6% in the first quarter. GAMMA Investing LLC now owns 2,961 shares of the company's stock worth $44,000 after acquiring an additional 1,173 shares in the last quarter. Summit Investment Advisors Inc. boosted its holdings in shares of Liquidia Technologies by 35.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock worth $78,000 after buying an additional 1,719 shares during the period. Quarry LP acquired a new position in Liquidia Technologies in the 1st quarter valued at $79,000. Finally, D. E. Shaw & Co. Inc. bought a new position in Liquidia Technologies in the 4th quarter worth $142,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia Technologies Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).